Kardigan has gone public with a $400 million initial public offering, built in large part on assets and talent left over from MyoKardia, according to BioPharma Dive.
The company's pitch to investors leaned on what it inherited rather than starting from scratch. CEO Tassos Gianakakos said that having late-stage assets, along with a team that had been fortified during their time at MyoKardia, "really resonated" with investors, according to BioPharma Dive.
The timing helped, too. Gianakakos noted that SpaceX's large public offering "didn't hurt either" — a sign that a buoyant market for high-profile listings can lift the prospects of companies going public around the same time, according to BioPharma Dive.
The broader takeaway is about how new biotech ventures get built. Rather than spinning up an unproven pipeline, Kardigan assembled a business around drug candidates and people that already carried a track record from MyoKardia. For investors weighing a young company, late-stage assets are generally seen as less risky than early experimental ones, because they are further along the path to potential approval.
The report frames the IPO as a case of turning "deal leftovers" into a sizable public debut — repackaging what remained after corporate dealmaking into a standalone company that the market was willing to fund at $400 million.
Why it matters: Kardigan's IPO shows how the leftovers of biotech dealmaking — proven assets and experienced teams — can be reassembled into a fundable new company, especially when a hot market for marquee listings is working in a company's favor.